Arrayit, Parkinson's Institute seek biomarkers

Jonathan Batchelor | | Health Imaging | Molecular Imaging
Life sciences technology developer Arrayit has formed a research collaboration with the Parkinson's Institute of Sunnyvale, Calif., to discover biomarkers for Parkinson's disease.

This study involves the prospective collection of samples from well-characterized Parkinson's patients utilizing two proprietary platforms: Arrayit's new H25K microarray and PlasmaScan 80. According to the Sunnyvale, Calif.-based Arrayit, the first studies have enabled rapid sample preparation of specimens from Parkinson's disease patients, which could lead to the discovery of molecular markers for Parkinson's disease.

Arrayit has created an antibody microarray containing monoclonal antibodies generated against native human plasma proteins. The PlasmaScan antibodies are provided by BioSystems International. They react with native human proteins with proper folding and post-translation modification to exhibit high antibody binding. The Arrayit microarray platform with the PlasmaScan monoclonal antibodies enables the exploration and identification of novel biomarkers in the human plasma proteome, the company said.

Jonathan Batchelor

Related Content

PET method offers new insight into inflammation of the brain
New PET imaging method could improve our understanding of long COVID
FDA approves new prostate cancer imaging agent with extended shelf life
New PET study offers insight into how dopamine drives executive function
New radiopharmaceutical targeted at gastrointenstinal cancers yields impressive results
New PET method combines antibody with radioactive isotope to improve lung cancer detection

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.